Guidelines for treatment of drug-susceptible tuberculosis and patient care
Uptsate 2017
After Workplace exposures and Sexual Assault
| DIRECTORATE: PRIMARY HEALTH CARE SERVICES
| DIVISION: PUBLIC AND ENVIRONMENTAL HEALTH
| SUB-DIVISION: OCCUPATIONAL HEALTH SERVICES
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Document No. : FDA/SMC/CTD/GL-CCT/2013/01
MMWR: Recommendations and Reports / Vol. 62 / No. 9
Morbidity and Mortality Weekly Report
October 25, 2013
The use of Delamanid and Bedaquiline for Children with Drug-Resistant Tuberculosis.
WHO/HTM/HIV/2007.01 WHO/HTM/TB/2007.380
Application of a One Health approach .
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillan...ce of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach.
more
Therapeutics Information and Pharmacovigilance Centre | TIPC
CORE Group has developed a module to improve preparedness for and response of communities in countries at risk of a cholera epidemic. The module consists of four lesson plans with accompanying flipcharts, intended to be delivered through community health workers. The lessons target mothers and careg...ivers of children under age five, a group that is at particular risk of death if infected. The module shares information about symptoms and risks; what families can do to prevent infection; how, when, and where to seek care; and what actions to take in the aftermath of an outbreak.
more
Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition
The Zimbabwe National Pharmacovigilance Policy Handbook, 2nd Edition updates the November 2013 version to indicate the Zimbabwe National Pharmacovigilance (PV) Centre’s compliance with the WHO Pharmacovigilance Indicators Handbook 2015.